Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Daraxonrasib→

Daraxonrasib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2765081-21-6
Molecular formula
C44H58N8O5S
Molecular weight
811.06 g/mol
Drug class
RAS(ON) multi-selective inhibitortargeted antineoplastic small molecule
Mechanism of action
Inhibits active GTP-bound RAS G12X and wild-type RAS signalling across multiple RAS isoforms, suppressing downstream MAPK pathway signalling in RAS-driven tumours.
Indications / reported uses
  • Treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy under the US FDA RASONQUE indication approved 26 August 2026

Sources: US FDA — Approval of daraxonrasib for metastatic pancreatic adenocarcinoma, 26 August 2026 · FDA Orphan Drug database — Daraxonrasib · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Daraxonrasib Environmental Risk Assessment (ERA) (the Daraxonrasib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.